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Objective: Traditionally, despite ventilation/perfusion mismatch, single lung 
transplantation has been the mainstay for end-stage chronic obstructive 
pulmonary disease. We t sted the hypothesis that bilateral sequential lung 
transplantation has better short- and intermediate-term results than single 
lung transplantation for chronic obstructive pulmonary disease. Methods: 
One hundred twenty-six consecutive lung transplants have been performed 
from November 1991 to March 1996. Seventy-six have been for chronic 
obstructive pulmonary disease. The diagnosis of this disease includes 
emphysema (80.3%), oq-antitrypsin deficiency (9.2%), lymphangioleiomyo- 
matosis (7.9%), and obliterative bronchiolitis (2.6%). Twenty-nine trans- 
plants have been bilateral and 47 have been single. Mean age was 55.3 for 
patients having single lung transplantation and 48.8 for those having 
bilateral ung transplantation (p = 0.001). The distribution of the diag- 
noses was similar between the two groups. At 6 months, there were 29 
survivors of single lung transplantation and 20 survivors of bilateral ung 
transplantation, with complete data for evaluation. Pulmonary function 
tests and 6-minute walk tests were evaluated at a mean of 15.4 and 12.8 
months after transplantation, respectively. Results: Sixty-day mortality was 
21.3% for single lung transplantation versus only 3.45% for bilateral ung 
transplantation (p = 0.03). Additionally, Kaplan-Meier analysis revealed 1- 
and 2-year survivals of 71.1% and 63.3% for single lung transplantation 
versus 90% and 90% for bilateral lung transplantation, respectively. 
Multiple major morbidities were analyzed. Primary graft failure was 
significantly reduced in the bilateral group (p = 0.049). Both 6-minute walk 
tests and forced expiratory volume in 1 second were improved from baseline 
by both single and bilateral ung transplantation (p = 0.001). Conclusions: 
Bilateral lung transplantation improves forced expiratory volume in 1 
second and 6-minute walk tests significantly over single lung transplanta- 
tion (p < 0.0001). Both perioperative mortality and Kaplan-Meier survival 
(to 3 years) are significantly improved when bilateral rather than single 
lung transplantation is used for chronic obstructive pulmonary disease in 
our series (p < 0.05). This is probably the result of significantly reduced 
primary graft failure. (J Thorac Cardiovasc Surg 1997;113:520-8) 
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C linical lung transplantation is indicated for sev- eral end-stage pulmonary conditions. They 
broadly include (1) septic lung disease, (2) pulmo- 
nary vascular disease, (3) restrictive lung disease, 
and (4) chronic obstructive pulmonary disease 
(COPD). Some indications include disease pro- 
cesses that encompass two or more of these subcat- 
egories (i.e., sarcoid). It was only natural that the 
first clinical lung transplant success for pulmonary 
fibrosis by Cooper and associates I was followed by 
renewed attempts to perform lung transplantation 
for COPD. 2 The initial successful lung transplanta- 
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Table I. Preoperative group demographics 
BLT SLT p Value 
Age 48.8 -- 9.7 55.3 _+ 6.6 0.001 
Sex (% male) 17/29 (58.6%) 13/47 (27.7%) 0.007 
Pco2 (mm Hg) 46.5 _+ 11.9 49.3 _+ 10.5 0.15 (NS) 
PAP (mm Hg) 37.9 _+ 11.2 35.8 _+ 7.01 0.19 (NS) 
FVC (L) 2.18 +_ 0.75 1.76 _+ 0.49 0.0097 
FEV t (L) 0.6 _+ 0.17 0.55 _+ 0.18 0.096 (NS) 
RV (L) 5.41 _+ 2.1 5.13 _+ 1.32 0.33 (NS) 
6MWT (feet) 712.7 _+ 238.1 677.1 _+ 290.8 0.26 (NS) 
Data are shown as mean -+ the standard eviation. PCOe, Carbon dioxide 
tension; PAP, pulmonary artery pressure; FVC, forced vital capacity; 
FEV1,volume exhaled in 1 second; RV, residual volume; 6MWT,, 6-minute 
walk test; NS, not significant. Pulmonary function test data were measured 
at the time of the initial evaluation and listing. 
tion operations for COPD included both heart-lung 
transplantation and double lung transplantat ion) '  4 
Two lungs were thought o be necessary to alleviate 
any severe ventilation/perfusion mismatch or poten- 
tial hyperinflationary mediastinal complications the- 
oretically possible with single lung transplantation 
(SLT).S, 6 In :1989, Mal and associates 7 reported the 
first clinical series of isolated SLT for COPD. A 
number of other eports followed thereafter, includ- 
ing the contribution of the San Antonio group, s-l° 
After these successful reports, there was significant 
enthusiasm for SLT as the procedure of choice for 
COPD. 11 The bilateral sequential lung transplanta- 
tion procedure (BLT) was then developed and 
reported in 1990 with excellent results. 12' 13 Since 
that time, over the past 3 to 4 years, a debate has 
been in progress regarding the question: Is BLT or 
SLT the optimal procedure for patients with end- 
stage COPD.  93,14 This is not simply a medical 
debate, because there are ethical and donor organ 
issues as well J  1 
This report analyzes, in a retrospective fashion, 
the results in our program comparing the outcomes 
of SLT and BLT for end-stage obstructive lung 
disease. Our decision algorithm for choosing BLT 
versus SLT for COPD has evolved since our initial 
lung transplant procedure for COPD in December 
1991. The intent of this analysis is to compare our 
consecutive series of BLTs with SLTs over the past 
4.25 years. 
Patients and methods 
Patients. Between November 1991 and March 1996, 
126 total lung transplants were performed by the Hospital 
of the University of Pennsylvania Lung Transplant Pro- 
gram in 123 patients. Seventy-six patients were operated 
on with a diagnosis of COPD. The diagnosis of COPD is 
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Fig. 1. Comparison of distribution of diagnoses in the 
two transplant recipient groups. There was no difference 
between groups (p = 0.09). A-I, &l-antitrypsin deficiency 
emphysema; LAM, lymphangioleiomymatosis; OB, oblit- 
erative bronchiolitis. 
defined to include generalized emphysema, cq-antitrypsin 
deficiency, lymphangioleiomyomatosis, and obliterative 
bronchiolitis. The vast majority of patients (>90%) have 
emphysema or c~l-antitrypsin deficiency. This series is a 
retrospective analysis of these 76 consecutive patients with 
COPD. One patient, who committed suicide at home with 
excellent pulmonary function after SLT, was excluded 
from the follow-up analysis. 
The first SLT for COPD was performed on December 
16, 1991 (transplant No. 2 in our program), and the first 
BLT for COPD was on July 13, 1993 (transplant No. 20 in 
our program). 
Methods. Pulmonary function, exercise ability, and he- 
modynamics were evaluated in all patients according to a 
standardized pretransplantation a d posttransplantation 
evaluation. This report examines the changes in forced 
expiratory volume in 1 second, forced vital capacity, 
residual volume, six-minute walk test, maximum oxygen 
uptake, blood gas determination i cluding carbon dioxide 
tension, and pulmonary artery pressure (measured in 
millimeters of mercury). All preoperative values were 
measured at the time of initial evaluation and listing. The 
mean time to transplantation was more than a year from 
the time of listing. Surviving patients are evaluated at 
3-month intervals. Mean follow-up time for the entire 
series of surviving patients was 14.6 months. 
Study design. Seventy-six patients were evaluated in 
this study, 61.8% of all patients who received lung trans- 
plantation from November 1991 to March 1996. The 
frequency of COPD has remained constant over the 
course of the entire program. Before September 1, 1994, 
61.5% of the recipients had COPD (40/65) versus 60% 
from September 1, 1994, to March 21, 1996 (36/60). This 
was somewhat surprising inasmuch as we anticipated a
reduction in the percentage of COPD diagnoses in the 
latter portion of our experience owing to the increased use 
of volume reduction as a bridge and alternative to lung 
transplantation. Most patients (but not all) who received a
volume reduction as a bridge were removed from the 
active lung transplant list. Of the 76 rec!pients with 
COPD, the BLT group (n = 29, 38.2%) received bilateral 
sequential ung transplants and SLT group (n = 47, 
61.8%) received single lung transplants. The distribution 
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Fig. 2. Forced vital capacity (FVC) before and after SLT and BLT. Standard error bars shown. Decreasing 
N numbers reflect number of patients tested at that time, i,o = 0.0097; 2p = 0.008; 3p = 0.006; 4p = 0.003,; 
5/) : 0.002; 6,0 = 0.024. 
Table I I .  Morbidity and major complications 
BLT SLT p Value 
Length of intubation (days) 2.43 _+ 1.75 8.13 ± 17.6 0.016 
Length of stay (days) 35.6 ± 40.4 30.7 ± 39.5 0.31 (NS) 
Obliterative bronchiolitis 2/28 (7.1%) 5/37 (13.5%) 0.4 (NS) 
Primary graft dysfunction 1/29 (3.45%) 9/47 (19.2%) 0.049 
Cerebrovascular ccident 5/29 (17.2%) 2/47 (4.3%) 0.057 (NS) 
Tracheostomy 4/29 (13.8%) 9/47 (19.2%) 0.5 (NS) 
Anastomosis 3/58 (5.2%) 1/47 (2.13%) 0.41 (NS) 
GI/OR 1/29 (3.45%) 7/47 (14.9%) 0.1 (NS) 
The obliterative bronchiolitis rate was calculated only for 60-day survivors. Anastomosis indicates the total number of anastomoses at risk necessitating 
operation, stenting, dilation, or laser therapy; GI/OR, gastrointestinal complications necessitating laparotomy or therapeutic endoscopy or a gastrointestinal 
hemorrhage of greater than 6 units that was treated conservatively; AS,not significant. 
of patients within the various categories of COPD is 
shown in Fig. 1. 
Immunosuppression. Our immunosuppression proto- 
cols have been based on a three-drug regimen for the 
duration of our transplant program. This regimen has 
included cyclosporine dosed to a level in the first year of 
approximately 250 to 350 ng/ml (after the first year it is 
reduced to 200 to 300 ng/ml), azathioprine 2 mg/kg daily, 
and prednisone, starting at 0.5 mg/kg daily and tapering to 
0.15 mg/kg per day by 6 months after transplant. At the 
very beginning of our program, we used routine induction 
antithymocyte gamma-globulin therapy instead of pred- 
nisone. Prednisone was then begun on the sixth postop- 
erative day. However, we changed to routine periopera- 
tire steroid immunosuppression very early in our 
experience (July 1992). Since transplant No. 60, we have 
added a "mini-induction" four-drug protocol for the first 
72 hours, because we have noted variable cyclosporine 
levels in the early postoperative period. This "mini- 
induction" technique added perioperative antithymocyte 
gamma-globulin to our standard azathioprine (Imuran), 
cyclosporine, and methylprednisolone sodium succinate 
(Solu-Medrol) until therapeutic cyclosporine l vels were 
achieved. 
Algorithm regarding decision to perform SLT versus 
BLT. The algorithm regarding the decision process of 
whether to perform an SLT versus a BLT evolved uring 
the period of this study. Early in our program the indica- 
tion for BLT for patients with COPD was limited to young 
patients (aged <45 years) with the diagnosis of al-anti- 
trypsin deficiency. By July 1993, the general indications 
for BLT had evolved to include (1) all patients with the 
diagnosis of ~l-antitrypsin deficiency and (2) all patients 
younger than 50 years of age. Presently (March 1996), we 
also perform BLT on all patients with lymphangio- 
leiomyomatosis in addition to ~a-antitrypsin deficiency 
and strongly consider BLT in all patients between 50 and 
59 years of age. 
Operative and anesthetic technique. The overwhelm- 
ing majority of patients having SLT were operated on via 
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Fig. 3. Forced expiratory volume in 1 second (FEV1) before and after SLT and BLT. Standard error bars 
shown, lp 0.096 (not significant); 2p = 2.38 x 10 4; 3p = 3.09 × 10-5; 4/) = 2.13 × 10-5; Sp = 9.34 × 10 5; 
6/) = 0.02. 
a standard posterolateral thoracotomy. Cardiopulmo- 
nary bypass was not necessarY for any of the SLT 
procedures. Recently we have favored use of a smaller 
anterolateral muscle-sparing thoracotomy for SLT (n = 
5). Since July 1, 1995, patients have received an anes- 
thetic technique that allows for extubation on the 
operating room table if possible (n = 7) for SLT 
recipients. Intravenous prostaglandin E is begun during 
the operation in all patients. 
BLT has been performed via an anterior bilateral 
thoracosternotomy approach] 3 Only one patient (3.3%) 
required cardiopulmonary b pass during BLT for COPD. 
No BLT recipient has been extubated on the operating 
room table. Both BLT and SLT recipients are subjected to 
a postprocedure therapeutic bronchoscopy in the operat- 
ing room and just before exiLubation. 
Statistical analyses. Student's t tests were used when 
comparing continuous numerical strings such as age, 
length of in-hospital stay, length of intubation, carbon 
dioxide tension, oxygen tension, maximum oxygen uptake, 
pulmonary function, and 6-minute walk test data between 
groups. )(2 Analysis was used to determine statistical 
significance of single-event, noncontinuous indices uch as 
morbidity and mortality rates. Kaplan-Meier survival es- 
timates required the use of the log rank (Mantel-Cox) 
method of X 2 analysis to determine Significance, compar- 
ing BLT versus SLT survivals. Statistical significance was 
defined as a p value less than 0.05. 
Results 
Definitions. The entire experience of this lung 
transplant program was reviewed. One hundred 
twenty-six transplant procedures were performed 
in 123 recipients. Seventy-six recipients (61.8%) 
had COPD. In our cohort of 76 recipients with 
COPD, 29 (38.2%) received BLTs (BLT group) 
and 47 (61.8%) received SLTs (SLT group). The 
broad definition of COPD considered for this 
study included emphysema, oq-antitrypsin defi- 
ciency emphysema, lymphangioleiomyomatosis, 
and obliterative bronchiolitis. The distribution of 
diagnoses in the SLT and BLT groups is shown in 
Fig. 1. 
Preoperative clinical characteristics. Clinical in- 
dices were compared between the two groups (BLT 
versus SLT) and are shown in Table I. Mean age was 
lower in the BET group and sex distribution was 
significantly different between the groups. Pre0per- 
ative functional status and comorbidity were evalu- 
ated and compared between BLT and SLT. Table I 
demonstrates that the SLT cohort was functionally 
different only with respect to preoperative forced 
vital capacity. The remainder of the pulmonary 
function test data show no significant difference 
between groups. Fig. 1, which shows the distribution 
of the indications for transplantation i the two 
groups, demonstrates no difference between BLT 
and SLT with respect to the underlying diagnosis 
(p = 0.09, not significant). 
Morbidity. Mean length of intubation (BLT 
2.43 _+ 1.75 days versus SLT 8.13 _+ 17.6 days; p = 
0.016) was significantly lower in the BLT group, 
despite the fact that seven recent SLT recipients 
were extubated on the operating room table. Mean 
length of in-hospital stay (BLT 35.6 _+ 40.4 clays 
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Fig. 4. Residual volume (RV) before and after SLT and BLT. Standard error bars shown, lp = 0.33 (not 
significant); 2p = 3.12 × 10-6; 3p = 3.83 × 10-4; 4p = 2.13 × 10 5; 5p = 2.06 × 10-6; 6/) = 0.002. 
versus SLT 30.7 _+ 39.5 days; p = 0.31, not signifi- 
cant) did not differ between the two groups. The 
incidence of major complications was examined and 
is shown in Table II. No significant difference was 
detected between the groups except in the case of 
primary graft failure, which was significantly lower 
in the BLT group (p = 0.049). Primary graft failure 
Was defined as a form of acute lung injury charac- 
terized by the presence of widespread pulmonary 
infiltrates within lung allograft(s) and associated 
hypoxemia nd ventilatory dependence xtending 
beyond the initial 5 postoperative days. The diagno- 
sis rests on exclusion of other causes of acute lung 
injury, including pneumonia, aspiration, volumetric 
overload, hyperacute r jection, massive blood prod- 
uct transfusion, or pulmonary venous outflow ob- 
struction. 15 
There was an increased risk of cerebrovascular 
accident in the BLT group (p = 0.057). Cerebrovas- 
cular accident/stroke was defined as any postopera- 
tive cerebrovascular ccident, including those that 
resolved without permanent residual deficit. Major 
gastrointestinal complications were defined as any 
complication ecessitating a laparotomy or thera- 
peutic endoscopic procedure or a gastrointestinal 
hemorrhage of more than 6 units treated conserva- 
tively. Rates of obliterative bronchiolitis, tracheos- 
tomy, and bronchial anastomotic omplications 
were no different between procedures. The diagno- 
sis of obliterative bronchiolitis was established on 
the basis of pulmonary function criteria as recently 
outlined by Cooper and associates 15as a decrement 
in forced expiratory volume in 1 second of more 
than 20% of posttransplantation baseline. 15-17 In 
one case in our series, the presence of obliterative 
bronchiolitis was confirmed histologically by post- 
mortem investigation of the lung. Additionally, 
phrenic nerve injury was studied and did not differ 
between groups. 
Functional outcome. Paired pulmonary function 
test data within the two groups were compared after 
transplantation. Twenty of the 29 BLT recipients 
and 29 of the 47 SLT recipients had paired data with 
mean follow-up times of 12.75 and 15.38 months, 
respectively. Figs. 2 to 5, which show posttransplan- 
tation functional and exercise outcomes (forced vital 
capacity, forced expiratory volume in 1 second, 
residual volume, and 6-minute walk test distance), 
demonstrate hat improvement in these values was 
considerably higher for the BLT group (statistical 
significance shown in legend). Mean maximum oxy- 
gen uptake after transplantation (BLT 65.2 _+ 16.6 
ml/min versus SLT 61.7 _+_ 15.8 ml/min expressed as 
a percent of the predicted value; p = 0.29, not 
significant) did not differ between the two groups. 
Mortality. The 60-day perioperative mortality 
rate (BLT 1/29 = 3.45% versus SLT 10/47 = 21.3%; 
p = 0.03) was lower in the BLT group. Cumulative 
survivals by Kaplan-Meier analysis, comparing the 
BLT versus SLT survival curves, were significantly 
different favoring BLT (p = 0.047) (Fig. 6). 
Of the three patients who died in the BLT group, 
one died of primary graft failure. The other two died 
of myocardial infarction and Guillain-Barr6 syn- 
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Fig. 5. Comparison of 6-minute walk (6MW) distance before and after SLT and BLT. Standard error bars 
shown. ~p = 0.26 (not significant); 2p = 0.16; 3p = 4.43 × 10-4; 4p = 0.06 (not significant); 5p = 0.015; 6p = 
0.022. 
drome at 2 weeks and 10 months, respectively, both 
with perfectly normal pulmonary function. Con- 
versely, the death rate for SLT recipients includes 
the earliest initial institutional experience and was 
significantly affected by the occurrence of primary 
graft failure. Our initial nine COPD transplants 
were all SLTs. The perioperative mortality rate was 
33% (3/9) and the crude 1-year survival only 44.4% 
(4/9). More recent 60-day mortality is 18.4% (7/38) 
if we exclude the first nine patients. These seven 
patients died of primary graft failure and adult 
respiratory distress yndrome (n = 4), sepsis (n = 
2), and cytomegalovirus pneumonitis (n = 1). Ad- 
ditionally, this 18.4% perioperative mortality rate 
can be compared more directly with the BLT group, 
as these two groups are concurrent, he transplan- 
tations having been done during the same time 
period (July 1993 to April 1996). 
Lymphangioleiomyomatosis was present in three 
patients in both the BLT and SLT groups. Two of 
the three patients with lymphangioleiomyomatosis 
in the SLT group died in the perioperative period. 
One still survives 4 years after transplantation. All 
three patients with lymphangioleiomyomatosis re- 
ceiving BLT are survivors. Two patients required 
transplantation because of obliterative bronchiolitis. 
Both were perioperative survivors. The SLT recipi- 
ent died of recurrent obliterative bronchiolitis 15 
months after transplantation. The BLT recipient is 
alive at 2 years. 
Discussion 
The history regarding which lung transplant pro- 
cedure is optimal for patients with end-stage COPD 
has been one of uncertainty. 11'18. 19 There have been 
theoretical concerns regarding SLT for COPD re- 
sulting from contralateral lung hyperexpansion a d 
severe ventilation/perfusion mismatch since the 
early 1970s. This theoretical concern was corrobo- 
rated by multiple reviews and analyses of the lung 
transplant experience at that time. 5' 6 Initially, after 
the success of heart-lung transplantation a d, sub- 
sequently, SLT for pulmonary fibrosis, lung trans- 
plantation for COPD was limited to either heart- 
lung transplantation r double lung transplantation, 
thereby obviating the theoretical concerns of SLT 
for COPD. The initial reports from France in 19897 
and subsequent reports from the United States 8' 10 
showed very successful clinical series of SLT for 
emphysema. At this time the conceptual framework 
regarding SLT as a viable transplant procedure for 
COPD was revisited. 9 SLT for emphysema was 
practiced widely, because it was noted that most 
patients with end-stage COPD from emphysema 
were between the ages of 50 and 65 years. However, 
patients considered for double lung transplantation 
or heart-lung transplantation were younger than 50 
years. Debate regarding the optimal ung transplant 
procedure for COPD resurfaced again after the orig- 
inal development and description of the BLT opera- 
tion. 12 This procedure greatly simplified the two- 
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lung transplant procedure, and in most cases it did 
not necessitate cardiopulmonary b pass and could 
safely be offered to patients up to 60 years of age. 13 
It was at this point in the evolution of lung trans- 
plantation that the competing considerations (im- 
proved functional outcome versus donor organ 
availability) complicated the decision-making pro- 
cess regarding the most appropriate and proper 
transplant procedure for end-stage COPD. 
This report represents an analysis of our consec- 
utive series of lung transplantations for COPD. The 
dilemma regarding which transplant procedure is 
optimal for patients with COPD is not resolved. 
Multiple groups have shown that many pulmonary 
functional parameters are improved in a statistically 
significant fashion with BLT over  8LT .  TM 18, 20 These 
results include statistically and significantly im- 
proved forced expiratory volume in 1 second, forced 
vital capacity, and residual volume. Our data cor- 
roborate these previous reports. Additionally, our 
data support he concept hat not only is standard 
pulmonary function test data improved with BLT 
versus SLT, but that exercise tolerance (measured 
by 6-minute walk tests) is significantly improved. 
Maximum oxygen uptake is slightly, but not signifi- 
cantly, higher in the BLT group. 
When we examine perioperative mortality and 
morbidity, our data show a statistically significant 
increase in Kaplan-Meier survival out to 3 and 4 
years (p < 0.05), as well as a statistically significant 
decrease in perioperative (60 day) mortality with the 
BLT procedure (p = 0.03). We realize that our 
21.3% perioperative SLT mortality rate is higher 
than expected. We had an early "learning curve," 
with 33% of our initial nine patients dying of 
primary graft failure in the perioperative period. 
Interestingly, even after eliminating our initial expe- 
rience and comparing a concurrent set of patients 
receiving the two procedures, we still had substan- 
tially increased perioperative mortality (18.4%) and 
primary graft failure (16.2%) in the SLT group. 
Regarding late mortality, we have no BLT deaths 
after 10 months. Unfortunately, there is a steady 
death rate after 1 year in the SLT group. 
Most major morbidities, as well as length of stay 
and total intubation time, were analyzed. The BLT 
group had significantly shorter periods of intubation 
and a significantly reduced incidence of primary 
graft dysfunction. The only perioperative morbidity 
that was increased in the BLT group was stroke, 
although the increase was not significant (p = 
0.057). The BLT procedure would theoretically have 
twice the deairing complications and a left atrial 
suture line twice the length of that needed for SLT. 
We have now implemented a policy of preoperative 
and intraoperative heparin administration with in- 
traoperative transesophageal chocardiography and 
postoperative subcutaneous heparin and aspirin. 
Other major morbidities were similar between the 
two procedures, including phrenic nerve injury, tra- 
cheostomy, and obliterative bronchiolitis. Our bron- 
chial anastomotic complication rate has been very 
low in this entire group of transplant recipients 
(3.8%). 
A very important issue regarding the decision- 
making process for patients considered for lung 
transplantation with COPD is organ availability. It is 
sometimes difficult to advocate the SLT procedure 
when our institutional data strongly support he use 
of BLT for COPD. On the other hand, SLT no 
doubt will allow more patients to undergo transplan- 
tation. 
Others have compared the BLT procedure with 
the SLT procedure. As in our report, the Washing- 
ton University Lung Transplant Program showed a 
very similar patient profile between the SLT and 
BLT groups at evaluation, except for mean age. As 
in our series, the BLT group was approximately 6 
years younger than the SLT group. Their 1-year 
mortality rate of 10.2% for SLT in COPD compares 
favorably with our 28.3% rate. On the other hand, 
their 16% 1-year mortality rate for BLT is greater 
than our 10.3% rate. is' 19 
In summary, the ideal decision algorithm for 
determining whether BLT is preferable to SLT is 
not available. We believe that the BLT procedure 
confers a definite advantage for pulmonary function. 
We have also demonstrated a statistically significant 
increase in exercise tolerance as measured by the 
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6-minute walk test and a slightly increased maxi- 
mum oxygen uptake in the BLT recipients. We have 
also noted slowly increasing residual volumes in SLT 
patients with chest x-ray evidence of a progressively 
expanding native lung. There has been a trend 
toward a decreased overall major complication 
rate with BLT, especially primary graft failure, 
although the: cerebrovascular ccidents are more 
prevalent. More long-term follow-up at the 3- to 
5-year period will be necessary to make a final 
determination f whether BLT is better than SLT 
for end-stage lung disease. However, it is interest- 
ing that in our data the BLT group has zero late 
mortality after 10 months whereas the SLT group 
has continued mortality after 1 year. Is this a sign 
that the BLT group tolerates obliterative bronchi- 
olitis, chronic rejection, and cytomegalovirus bet- 
ter than the SLT group? This question eeds more 
analysis. 19 
Presently in our program, we preferentially offer 
the BLT procedure to all patients with al-antitry p-
sin deficiency. Additionally, we offer the BLT pro- 
cedure to all patients with lymphangioleiomyomato- 
sis, and we strongly consider the BLT option for 
patients younger than 55 years. We even consider 
BLT selectively for patients between the ages of 55 
and 60, although the three deaths (10.3%) in our 
BLT group occurred in patients who were 60, 59, 
and 57 years of age. In addition, one of the more 
severe, nonlethal strokes occurred in a BLT recipi- 
ent who was 62 years of age. Finally, two 59-year-old 
BLT recipients, who have since done well, required 
three major laparotomies for life-threatening gas- 
trointestinal complications. We therefore continue 
to believe that the simple and very straightforward 
SLT procedure isoptimum in most patients over the 
age of 55 years. Indeed, recently we have been using 
muscle-sparing small anterior thoracotomy incisions 
and intraoperative extubation for most SLT proce- 
dures. 
We believe that this information supports the 
recent ransplant trend toward increased use of the 
BLT procedure for COPD. The short- and interme- 
diate-term superiority of BLT over SLT most prob- 
ably results from an initial reduction in primary graft 
failure and longer-lasting improvement in pulmo- 
nary function. 
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Discussion 
Dr. Thomas J. Kirby (Cleveland, Ohio). Would you 
please clarify your exact rationale for undertaking BLT in 
the setting of emphysema? BLT is known in the transplant 
community to give better results than SLT in terms of 
pulmonary function tests and exercise tolerance. In the 
abstract you used the word "hypothesis" when comparing 
the superiority of BLT over SLT. There is nothing hypo- 
thetical about the improved functional results of BLT 
compared with SLT. There may be some controversy in 
terms of mortality, and that leads to my next question. 
The significant mortality that you report in your SLT 
group is not the experience of others; in fact, at most 
centers SLT for emphysema carries the lowest mortality. 
You reported a 60-day mortality of 22.5% for SLT 
compared with a 4.2% 60-day mortality for BLT. This is a 
very unusual experience and should not be used to justify 
or support he use of BLT in emphysema. In our experi- 
ence with 36 SLTs carried out for emphysema, we had a 
60-day mortality of 4.7% and a 1-year survival of 85%. 
Could you elaborate the reasons for your increased mor- 
tality in the SLT group? 
Last, and I think most important, donor shortage 
remains a critical problem in the United States for all 
major organ transplants and in particular for lung trans- 
plantation. The number of patients on waiting lists is 
rapidly dwarfing the number of lung transplants per- 
formed. The waiting list mortality for lung transplantation 
around the United States varies between 15% to 20% per 
year, which is not an insignificant figure. 
Dr. Bavaria, do you think that your improved functional 
results with BLT justify using two lungs when in most 
surgeons' hands the two lungs would have been used for 
two separate recipients? 
Dr. Bavaria. Thank you, Dr. Kirby. Those are all very 
cogent points. 
The first question was, why use a BLT. In our experi- 
ence, we have noticed a decreased incidence of primary 
graft dysfunction. Increased primary graft dysfunction has 
led to both increased morbidity and mortality in our SLT 
group. Only one of 30 patients with BLT had primary graft 
dysfunction. So I believe it is not just the improved 
functional parameters that have led us toward bilateral 
transplantation in this group, but both reduced early graft 
dysfunction and better long-term results on pulmonary 
function tests and exercise improvement. 
The issue of morbidity and mortality in our experience 
is a critical one and is actually one of the limitations of this 
study. We did have a learning curve or an increased 
mortality rate early on in the experience, but, even so, the 
BLT group did better than the SLT group. I do not have 
any other explanation for that except hat primary graft 
dysfunction is the single biggest problem with SLT in our 
experience, and we simply do not have that problem in our 
BLT cohort. 
Third, I think the answer to the donor availability 
question is to expand the donor pool. Many of our BET 
patients received lungs that we would not have used for an 
SLT. I resist performing an SLT if the donor has problems 
and a decreased oxygen tension, say, below 400 mm Hg, 
whereas I will use a BLT lung block with an oxygen 
tension of 250 mm Hg because of the increased margin. I
think the use of "marginal BLT blocks" may actually 
increase our donor pool. 
Dr. G. Alexander Patterson (St. Louis, Mo.). I was 
struck by the prevalence of cerebrovascular ccidents in 
your series, five cases in the BLT group. Would you 
comment on the technique you used to deair the 
allograft at the time of the procedure? We are partic- 
ularly meticulous about that. We rinse the pulmonary 
artery and the venous anastomosis and deair ante- 
gradely through an open left atrial anastomosis, both 
from the pulmonary artery side and from the left atrial 
side. We make absolutely certain to achieve a good 
deairing on the first graft, because as the table is rotated 
with that graft down, an embolic event is more likely to 
occur. I would appreciate your comments on how you 
deair the allograft. 
Dr. Bavaria. We have actually looked at this point in 
great detail. Of the five strokes, only one of them was an 
embolic air stroke (the patient recovered completely); 
three of them were caused by embolic particulate matter, 
and one of them was the result of a low-flow situation. 
We deair in a standard fashion. I make a wide open left 
atrial hole before removing the left atrial clamp and 
actually allow quite a bit of blood to flow out. The 
pulmonary artery is left partially open, and the lungs are 
inflated a little bit before the left atrial clamp is released. 
Basically, it is the St. Louis method that Dr. Larry Kaiser 
brought with us. We also place the patient in the Tren- 
delenburg position and try very hard to keep an intima- 
to-intima anastomosis. The one change we have made is 
to now institute perioperative heparin therapy (2000 units 
intravenously before clamps are placed). 
